| Ivana Magovcevic-Liebisch |
Ivana Magovcevic-Liebisch is on the board of Aeglea Biotherapeutics, Inc., Suffolk University and Applied Genetic Technologies Corp. and Chief Business Officer & Executive Vice President at Ipsen SA.
In her past career she held the position of Chief Strategy & Development Officer, Executive VP at Axcella Health, Inc., Senior VP & Head-Global Business Development at Teva Pharmaceutical Industries Ltd., Chief Operating Officer & Executive Vice President of Dyax Corp. and Director-Intellectual Property & Patent Counsel at Transkaryotic Therapies, Inc.
She received a doctorate from Harvard University, a graduate degree from Suffolk University Law School and an undergraduate degree from Wheaton College (Illinois). |
| Stephen W. Potter |
Stephen W. Potter is Chief Business Officer & Vice President at Applied Genetic Technologies Corp.
He previously held the position of Executive Vice President for Caladrius Biosciences, Inc. and Executive Vice President of NeoStem, Inc. (a subsidiary of Caladrius Biosciences, Inc.), SVP-Operations & Corporate Development at Osiris Therapeutics, Inc. and Senior Vice President-Business Development at Genzyme Corp.
He received an undergraduate degree from the University of Massachusetts and an MBA from Harvard Business School. |
| Ed M. Hurwitz |
Mr. Ed M. Hurwitz is a Managing Director at MPM Capital LP, Chairman at Viewpoint Therapeutics, Inc., a Manager at Alta Embarcadero Biopharma Partners III LLC and a Managing Director at Precision BioVentures LLC. He is on the Board of Directors at Applied Genetic Technologies Corp., Calistoga Pharmaceuticals, Inc., MacroGenics, Inc., Alta BioPharma Management III LLC, Alta Partners VIII LP and Avid Radiopharmaceuticals, Inc.
Mr. Hurwitz was previously employed as an Independent Director by Sunesis Pharmaceuticals, Inc., an Independent Director by CARA Therapeutics, Inc., and Chief Financial Officer & Senior Vice President by Affymetrix, Inc. He also served on the board at Alta Partners Management Corp., FoldRx Pharmaceuticals, Inc. and Taligen Therapeutics, Inc.
Mr. Hurwitz earned his JD and MBA degrees from the University of California, Berkeley's Boalt School of Law and Haas School of Business, and his BA in Molecular Biology from Cornell University. |
| Anne M. VanLent |
Anne M. VanLent founded AMV Advisors and Technology Compass Group LLC. Currently, she is President of AMV Advisors. Ms. VanLent is also on the board of International AIDS Vaccine Initiative, Inc., Applied Genetic Technologies Corp., Trevi Therapeutics, Inc. and Vaxart, Inc.
Anne M. VanLent previously held the position of Principal at Technology Compass Group LLC, Chief Financial Officer & Executive Vice President of Barrier Therapeutics, Inc., Chief Financial Officer & Senior Vice President of The Liposome Co., Inc. and Executive Vice President-Portfolio Management at Sarnoff Corp.
Anne M. VanLent received an undergraduate degree from Mount Holyoke College. |
| Arnold Lewis Oronsky |
Currently, Arnold Lewis Oronsky occupies the position of Chairman for EpicentRx, Inc., Chairman of Dynavax Technologies Corp. and Managing Director at InterWest Partners, LLC. He is also General Partner for Interwest Venture Management Co. and on the board of 13 other companies.
Dr. Oronsky previously occupied the position of Vice President-Discovery Research at Lederle Laboratories, Head-Inflammation, Allergy & Immunology Research at Ciba-Geigy Corp., Head-Inflammation, Allergy & Immunology at Ciba-Geigy Pharmaceuticals and Vice President-Discovery Research at Wyeth Holdings LLC.
Dr. Oronsky received a doctorate from Columbia University and an undergraduate degree from New York University. |
| Emmie Chang |
Founder of Camperoo, Inc., Emmie Chang is Secretary at Applied Genetic Technologies Corp. Ms. Chang is also Partner at Foley Hoag LLP.
Ms. Chang previously was Chief Executive Officer at Camperoo, Inc. |
| Scott E. Koenig |
Founder of MacroGenics, Inc., Scott E. Koenig presently holds the position of Chairman at Applied Genetic Technologies Corp. and President, Chief Executive Officer & Director at MacroGenics, Inc. Dr. Koenig is also on the board of Biotechnology Innovation Organization, GlycoMimetics, Inc. and The International Biomedical Research Alliance and Member of Cornell University Council.
In his past career he held the position of Senior Vice President-Research at Medimmune, Inc., Principal at National Institute of Allergy & Infectious Diseases, Chairman at Children's Research Institute, Inc., Principal at National Institutes of Health and Trustee-Advisory Board at Cornell University.
Scott E. Koenig received a doctorate and an undergraduate degree from Cornell University and a doctorate from The University of Texas Health Science Center at Houston. |
| Susan B. Washer |
Presently, Susan B. Washer is President, Chief Executive Officer & Director at Applied Genetic Technologies Corp. She is also on the board of 8 other companies.
In her past career Ms. Washer held the position of President & Chief Executive Officer for Scenic Productions, Inc., Principal at Eli Lilly & Co. and Principal at Abbott Laboratories (Pakistan) Ltd.
She received an undergraduate degree from Michigan State University, an MBA from Warrington College of Business Administration and an MBA from the University of Florida. |
| James Rosen |
Mr. James Rosen is an Independent Director at Applied Genetic Technologies Corp., a Principal at Intersouth Partners, a Chief Executive Officer at Artizan Biosciences, Inc., a Director-Public Health Foundation at Unc Gillings School of Global Public Health and a Partner at Intersouth Associates VI LLC. He is on the Board of Directors at Applied Genetic Technologies Corp.
Mr. Rosen was previously employed as an Equity Research Analyst by Brean Murray & Co., a Principal by Duke University Medical Center, and a Principal by The Robert Wood Johnson Foundation. He also served on the board at Viamet Pharmaceuticals Corp., Advanced Animal Diagnostics, Inc., Viamet Pharmaceuticals, Inc., 480 Biomedical, Inc. and Public Health Foundation.
He received his undergraduate degree from Duke University, a graduate degree from Unc Gillings School of Global Public Health and an MBA from Kenan-Flagler Business School. |
| William E. Aliski |
William E. Aliski is on the board of Ultragenyx Pharmaceutical, Inc., Applied Genetic Technologies Corp. and X4 Pharmaceuticals, Inc. Mr. Aliski previously held the position of General Manager-BioMarin Europe at BioMarin Pharmaceutical, Inc. and Vice President & General Manager at BioMarin Europe Ltd. (a subsidiary of BioMarin Pharmaceutical, Inc.), Vice President-Patient & Product Services at Genzyme Corp., Chief Commercial Officer & Senior Vice President at FoldRx Pharmaceuticals, Inc. and Vice President-Commercial Operations at Transkaryotic Therapies, Inc.
He received an undergraduate degree and a graduate degree from Boston College and a graduate degree from Harvard Kennedy School of Government. |
| William A. Sullivan |
Founder of District Cider Co., Inc., William A. Sullivan currently holds the position of President at District Cider Co., Inc., Chief Financial Officer of Applied Genetic Technologies Corp. and Associate for TA Associates Management LP.
In the past he held the position of Treasurer, Chief Financial & Accounting Officer at Merrimack Pharmaceuticals, Inc. and Controller at Vette Corp.
He received an undergraduate degree from Williams College and a graduate degree and an MBA from Northeastern University. |
| Matthew Feinsod |
Matthew Feinsod founded Imagen Biotech, Inc. He is Chief Medical Officer at Imagen Biotech, Inc. and EVP-Global Strategy & Development at Applied Genetic Technologies Corp. He is also on the board of World Eye Mission.
In his past career Dr. Feinsod was Medical Officer at US Food & Drug Administration, Senior VP-Strategy & Product Development at Eyetech Pharmaceuticals, Inc. and Director-University Hospitals Institutional at George Washington University.
He received a doctorate from George Washington University and an undergraduate degree from The Wharton School of the University of Pennsylvania. |
| Mark S. Shearman |
Presently, Mark S. Shearman holds the position of Chief Scientific Officer & Vice President at Applied Genetic Technologies Corp.
In his past career Dr. Shearman held the position of Senior Director at Merck Sharp & Dohme Research Laboratories and Senior VP-Research & Early Development at EMD Serono, Inc.
He received an undergraduate degree from the University of Bristol and a doctorate from The University of Nottingham. |
| Karen M. Carroll |
Karen M. Carroll is Vice President-Clinical Development Operations at Applied Genetic Technologies Corp. |
| Brian Krex |
Presently, Brian Krex holds the position of General Counsel for Applied Genetic Technologies Corp.
In his past career Mr. Krex was Associate at Moses & Singer LLP, Chief Counsel & Assistant General Counsel at Pfizer Inc. and VP, Global Head-Commercial & Regulatory Law at Alexion Pharmaceuticals, Inc.
He received an undergraduate degree from Bard College and a graduate degree from Seton Hall University School of Law. |
| Nnenna Ihekoromadu |
Currently, Nnenna Ihekoromadu is VP-Clinical Research & Medical Affairs at Applied Genetic Technologies Corp. |
